Evidence map›Paper›PMID 29386280›Full record

SynthesisNeurology2018

Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.

Andreas Charidimou, Jan O Friedrich, Steven M Greenberg, Anand Viswanathan

Open access · bronzeAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Pooled it
  4. Article
  5. Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Clinical Management of Cerebral Amyloid Angiopathy.Journal of clinical medicine · 2025
    Review
  10. Article
  11. Circulating proteomic biomarkers for cerebral amyloid angiopathy screening and risk stratification.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  13. Article
  14. Biomarkers Unveiling the Interplay of Mind, Nervous System, and Immunity.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  15. Cerebral amyloid angiopathy: a narrative review.Frontiers in aging neuroscience · 2025
    Review
  16. Article
  17. Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andreas CharidimouFrom the Stroke Research Center (A.C., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.O.F.) and Interdepartmental Division of Critical Care (J.O.F.), University of Toronto; and Critical Care and Medicine Departments and Li Ka Shing Knowledge Institute (J.O.F.), St. Michael's Hospital, Toronto, Canada. andreas.charidimou.09@ucl.ac.uk.
Jan O FriedrichFrom the Stroke Research Center (A.C., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.O.F.) and Interdepartmental Division of Critical Care (J.O.F.), University of Toronto; and Critical Care and Medicine Departments and Li Ka Shing Knowledge Institute (J.O.F.), St. Michael's Hospital, Toronto, Canada.
Steven M GreenbergFrom the Stroke Research Center (A.C., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.O.F.) and Interdepartmental Division of Critical Care (J.O.F.), University of Toronto; and Critical Care and Medicine Departments and Li Ka Shing Knowledge Institute (J.O.F.), St. Michael's Hospital, Toronto, Canada.
Anand ViswanathanFrom the Stroke Research Center (A.C., S.M.G., A.V.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Medicine (J.O.F.) and Interdepartmental Division of Critical Care (J.O.F.), University of Toronto; and Critical Care and Medicine Departments and Li Ka Shing Knowledge Institute (J.O.F.), St. Michael's Hospital, Toronto, Canada.
University of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo perform a meta-analysis of 4 core CSF biomarkers (β-amyloid [Aβ]42, Aβ40, total tau [t-tau], and phosphorylated tau [p-tau]) to assess which of these are most altered in sporadic cerebral amyloid angiopathy (CAA).

methodsWe systematically searched PubMed for eligible studies reporting data on CSF biomarkers reflecting amyloid precursor protein metabolism (Aβ42, Aβ40), neurodegeneration (t-tau), and tangle pathology (p-tau) in symptomatic sporadic CAA cohorts vs controls and patients with Alzheimer disease (AD). Biomarker performance was assessed in random-effects meta-analysis based on ratio of mean (RoM) biomarker concentrations: (1) in patients with CAA vs healthy controls and (2) in patients with CAA vs patients with AD. RoM >1 indicates higher biomarker concentration in patients with CAA vs comparison population and RoM <1 indicates higher concentration in comparison groups.

resultsThree studies met inclusion criteria. These comprised 5 CAA patient cohorts (n = 59 patients) vs healthy controls (n = 94 cases) and AD cohorts (n = 158). Three core biomarkers differentiated CAA from controls: CSF Aβ42 (RoM 0.49, 95% confidence interval [CI] 0.38-0.64,

conclusionSpecific CSF patterns of Aβ42, Aβ40, t-tau, and p-tau might serve as molecular biomarkers of CAA, but analyses in larger CAA cohorts are needed.

Indexed as

Amyloid beta-PeptidesBiomarkersCerebral Amyloid AngiopathyHumansPeptide Fragmentstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau Proteins

Identifiers

PMID29386280
PMCPMC5837868
OpenAlexW2785562111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.